Am J Transplant, Volume 20, Suppl 3 Archives - Page 5 of 223 - ATC Abstracts

2020 American Transplant Congress
Belatacept Monthly Therapy: Transplant Recipients’ Experience
S. N. Little¹, É. N. Arsenault Knudsen², D. A. Mandelbrot¹
¹Transplant, University of Wisconsin Hospital and Clinics, Madison, WI, ²University of Wisconsin Hospital and Clinics, Madison, WI
*Purpose: While graft and patient outcomes with belatacept have been relatively well documented, the decision to use belatacept for kidney transplant recipients rests in part…
2020 American Transplant Congress
A Multicenter, Randomized, Controlled Trial to Steer Immunosuppressive Therapy by Virus-Specific T Cells after Pediatric Kidney Transplantation (IVIST-Trial)
T. Ahlenstiel-Grunow¹, A. Großhennig¹, R. Schild², J. Oh², C. Taylan³, L. Weber³, H. Staude⁴, M. Verboom¹, C. Schröder¹, R. Sabau¹, A. Koch¹, X. Liu¹, L. Pape¹
¹Hannover Medical School, Hannover, Germany, ²University Hospital Hamburg-Eppendorf, Hamburg, Germany, ³University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany, ⁴University Hospital of Rostock, Rostock, Germany
*Purpose: Pharmakokinetic monitoring of immunosuppressants alone is insufficient to estimate the individual intensity of immunosuppression after kidney transplantation (Tx). Virus-specific T cells (Tvis) correlate with…
2020 American Transplant Congress
Single-Dose Anti-Thymocyte Globulin is Non-Inferior to Divided-Dose for Induction Therapy in Kidney and Pancreas Transplantation
A. I. Ingemi¹, O. F. Bangash¹, S. McCoy¹, L. Hulse², J. Colonna¹, H. Sadr¹, S. Sutton¹, M. Coleman¹, T. Wilson¹, T. R. McCune¹
¹Sentara Norfolk General Hospital, Norfolk, VA, ²Children's Hospital of the King's Daughters, Norfolk, VA
*Purpose: Emerging studies suggest that single-dose rabbit antithymocyte globulin (rATG) is not inferior to the divided-dose, however this dosing strategy has never been evaluated in…
2020 American Transplant Congress
Novel Treatment of Acute Antibody-Mediated Rejection in a Nonhuman Primate Model of Kidney Allotransplantation
R. Schmitz¹, Z. W. Fitch¹, A. Y. Choi¹, M. Manook¹, J. Yoon¹, J. D. Lambris², J. Kwun¹, S. J. Knechtle¹
¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience acute antibody mediated rejection (AMR) with limited treatment options. We tested a novel treatment strategy for…
2020 American Transplant Congress
Quantifying Gender-Based Disparties in Liver Allocation: A Path Forward
B. A. Shelton¹, K. Olthoff², E. Pomfret³, K. A. Forde², D. Sawinski⁴, M. Gray¹, N. Ascher⁵, J. E. Locke¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³University of Colorado School of Medicine, Denver, CO, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of California at San Francisco School of Medicine, San Francisco, CA
*Purpose: Differences in local organ supply and demand have introduced geographic inequities in the Model for End-stage Liver Disease (MELD) based liver allocation system prompting…
2020 American Transplant Congress
Outcomes Following Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma: A Matched Analysis
M. L. Holzner¹, F. Parvin-Nejad², K. Fei³, S. Florman¹, M. E. Schwartz¹, P. Tabrizian¹
¹Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: Mixed hepatocellular-cholangiocarcinoma (HCC-CC) is a biphenotypic liver cancer thought to have unfavorable tumor biology and a poor prognosis. Surgical outcomes of HCC-CC remain unclear.…
2020 American Transplant Congress
Do the Characteristics of Donor Specific Antibody Truly Predict Severity of Cardiac Allograft Vasculopathy Late after Transplantation?
K. Nishihara, J. Patel, M. Kittleson, D. Chang, E. Kransdorf, D. Geft, A. Shen, L. Czer, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: The development of donor specific antibody (DSA) has been correlated to the development of cardiac allograft vasculopathy (CAV) after heart transplantation. However, it has…
2020 American Transplant Congress
Understanding the Molecular Phenotype of Kidney Injury
J. Reeve¹, P. Halloran¹, &. the INTERCOMEX Study Group²
¹University of Alberta, Edmonton, AB, Canada, ²., ., AB, Canada
*Purpose: The injury status of transplanted organs is a strong predictor of graft loss. We used injury-related gene expression to explore the relationship between function,…
2020 American Transplant Congress
A Single Centre Report of Renal Transplantation Against a Positive Crossmatch Due to HLA-DP Donor Specific Antibodies without Prior Antibody Removal
Y. Marie¹, T. Key², A. Halawa¹
¹Renal Transplantation, Sheffield Kidney Institute, Sheffield, United Kingdom, ²2.Department of Histocompatibility and Immunogenetics, Sheffield, United Kingdom
*Purpose: In renal transplantation, the clinical effects of donor specific antibodies (DSA) against HLA-DP are unclear. We report successful kidney transplants in three highly sensitised…
2020 American Transplant Congress
Survival Benefit of Accepting Kidneys with Acute Kidney Injury
Y. Yu, J. Long, M. Bowring, S. Yu, J. Motter, T. Ishaque, J. Garonzik Wang, A. Massie, D. Segev
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Accepting an acute kidney injury kidney (AKI) or remaining on the waitlist to receive a better offer is under discussed due to the worse…

« Previous Page
1
…
3
4
5
6
7
…
223
Next Page »